News Center
News Type
Qingfeng will attend the 2026 J.P. Morgan Healthcare Conference
Qingfeng Pharmaceutical Group will participate in BIO Partnering @ JPM Week 2026, which will take place in San Francisco from January 12–15, 2026.
Kvvit Pharma Unveils Dual Breakthroughs in CNS Therapeutics at Prestigious SfN-2025 Conference
At the Society for Neuroscience 2025 meeting (SfN-2025), Jiangxi Kvvit Pharmaceutical showcased promising data on two drug candidates. KR232 is a next-generation treatment for schizophrenia, and KR233 has best-in-class potential for epilepsy. These presentations highlight Kvvit's growing pipeline focused on unmet needs in CNS disorders.
Single-Dose Treatment! China’s First Novel Antiviral Influenza Drug Yisuda® Approved for Market
On March 27, 2025, Kvvit Pharmaceuticals, a subsidiary of Qingfeng Pharmaceutical Group, received approval to market Yisuda® Suraxavir Marboxil Tablets.
First Domestic Approval! Qingfeng Pharmaceutical’s Vancomycin Hydrochloride for Oral Solution Officially Approved for Market
On March 11, Qingfeng Pharmaceutical’s subsidiary, Corey Pharmaceuticals, received official approval from China’s National Medical Products Administration (NMPA) for its oral vancomycin hydrochloride solution, becoming the first company in China to obtain authorization for this product.
First Domestic Approval! Qingfeng Receives NMPA Approval for First Generic Pirampanel Oral Suspension
On March 21, Qingfeng Pharmaceutical’s subsidiary, Kvvit Pharmaceuticals, obtained NMPA approval to market the first domestically developed generic piracetam oral suspension.
Qingfeng and Kexing Biopharm Join Forces for Global Enzalutamide Launch
On January 16, Qingfeng Pharmaceutical Group’s subsidiary, Corey Pharmaceuticals, and Kexing Biopharm (688136.SH) officially signed an agreement to work together on the international promotion of Enzalutamide soft capsules.
